Literature DB >> 35992261

Terlipressin and albumin: The good, the bad, and the unattractive (with apologies to Sergio Leone).

Mahmoud Omar1,2, Trana Hussaini3, Eric M Yoshida1.   

Abstract

Entities:  

Keywords:  albumin; hepatorenal syndrome; terlipressin

Year:  2021        PMID： 35992261      PMCID： PMC9202772          DOI： 10.3138/canlivj-2021-0010

Source DB:  PubMed          Journal:  Can Liver J        ISSN： 2561-4444


× No keyword cloud information.
  10 in total

Review 1.  Hepatorenal syndrome.

Authors:  Pere Ginès; Elsa Solà; Paolo Angeli; Florence Wong; Mitra K Nadim; Patrick S Kamath
Journal:  Nat Rev Dis Primers       Date:  2018-09-13       Impact factor: 52.329

2.  Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

Authors:  Marta Cavallin; Patrick S Kamath; Manuela Merli; Silvano Fasolato; Pierluigi Toniutto; Francesco Salerno; Mauro Bernardi; Roberto Giulio Romanelli; Cosimo Colletta; Freddy Salinas; Antonio Di Giacomo; Lorenzo Ridola; Ezio Fornasiere; Paolo Caraceni; Filippo Morando; Salvatore Piano; Angelo Gatta; Paolo Angeli
Journal:  Hepatology       Date:  2015-02-13       Impact factor: 17.425

Review 3.  Kidney Injury in Liver Disease.

Authors:  Kevin R Regner; Kai Singbartl
Journal:  Crit Care Clin       Date:  2016-07       Impact factor: 3.598

4.  Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

Authors:  Thomas D Boyer; Arun J Sanyal; Florence Wong; R Todd Frederick; John R Lake; Jacqueline G O'Leary; Daniel Ganger; Khurram Jamil; Stephen Chris Pappas
Journal:  Gastroenterology       Date:  2016-02-16       Impact factor: 22.682

5.  Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

Authors:  Florence Wong; S Chris Pappas; Michael P Curry; K Rajender Reddy; Raymond A Rubin; Michael K Porayko; Stevan A Gonzalez; Khalid Mumtaz; Nicholas Lim; Douglas A Simonetto; Pratima Sharma; Arun J Sanyal; Marlyn J Mayo; R Todd Frederick; Shannon Escalante; Khurram Jamil
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

6.  Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.

Authors:  Salvatore Piano; Hartmut H Schmidt; Xavier Ariza; Alex Amoros; Antonietta Romano; Anna Hüsing-Kabar; Elsa Solà; Alexander Gerbes; Mauro Bernardi; Carlo Alessandria; Bernhard Scheiner; Marta Tonon; Miriam Maschmeier; Cristina Solè; Jonel Trebicka; Thierry Gustot; Frederik Nevens; Vicente Arroyo; Pere Gines; Paolo Angeli
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 11.382

7.  Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.

Authors:  Marta Cavallin; Salvatore Piano; Antonietta Romano; Silvano Fasolato; Anna Chiara Frigo; Gianpiero Benetti; Elisabetta Gola; Filippo Morando; Marialuisa Stanco; Silvia Rosi; Antonietta Sticca; Umberto Cillo; Paolo Angeli
Journal:  Hepatology       Date:  2016-02-03       Impact factor: 17.425

8.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Authors:  Marta Martín-Llahí; Marie-Noëlle Pépin; Mónica Guevara; Fernando Díaz; Aldo Torre; Alberto Monescillo; Germán Soriano; Carlos Terra; Emilio Fábrega; Vicente Arroyo; Juan Rodés; Pere Ginès
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

9.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

Review 10.  An Integrated Review of the Hepatorenal Syndrome.

Authors:  Alicia S Ojeda-Yuren; Eira Cerda-Reyes; Maria R Herrero-Maceda; Graciela Castro-Narro; Salvatore Piano
Journal:  Ann Hepatol       Date:  2020-08-23       Impact factor: 2.400
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.